Adalimumab is a fully human, high-affinity, recombinant immunoglobulin G (IgG) anti-TNF alpha monoclonal antibody. It is a molecule comprising 1330 amino acids and has a molecular weight of approximately 148 kDa. It inhibits the binding of TNF alpha (both soluble and membrane-bound). It inhibits its interaction with p55 (TNFR1) and p75 (TNFR2) cell surface TNF receptors, which in turn interferes with cytokine-driven inflammatory processes. Adalimumab is a biologic drug that blocks the development of inflammation in the gastrointestinaltract.